Clinical trial
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human…
NCT00350272 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00350272 |
|---|---|
| Title | Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants |
| Official title | A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected Treatment-naive Participants. There is a 36 Week, Open-label, Extension Phase for Eligible Participants. |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Collaborators | Achillion, a wholly owned subsidiary of Alexion Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Elvucitabine, Lamivudine, Tenofovir, Efavirenz |
| Enrollment | 76 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Apr 1, 2009 |
| First posted | Jul 10, 2006 |
| Last update posted | Aug 30, 2023 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: